David R. Bauer
Lawyers
Filters
Turn Therapeutics direct listing
We advised Turn Therapeutics on its Nasdaq listing
Neptune $368 million IPO
The shares are listed on the New York Stock Exchange
Amulet Capital Partners sale of SSI Strategy to Clinigen
We are advising Amulet Capital Partners and SSI Strategy on the sale
Medtronic €1.5 billion notes offering
The investment-grade notes are due 2030 and 2045
MBX Biosciences $200 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Oscar Health $410 million convertible senior subordinated notes and capped call transactions
The 2.25% convertible notes are due 2030
Bruker mandatory convertible preferred stock offering
The preferred stock will be listed on Nasdaq
Precigen $125 million financing
We advised Precigen on the loan agreement
Eli Lilly $6.75 billion notes offering
The investment-grade offering consisted of seven tranches
Zoetis $1.85 billion senior notes offering
The investment-grade notes are due 2028 and 2035